Alec Van Gelder: Novo Nordisk Opens Global Patient Advocacy Role for Haemoglobinopathies
Alec Van Gelder, Vice President of Corporate Affairs, Rare Disease at Novo Nordisk, shared a post on LinkedIn:
“We’re Hiring: Associate Director, Patient Advocacy – Haemoglobinopathies at Novo Nordisk Rare Disease.
With recent progress in Sickle Cell Disease marking a pivotal moment for the haemoglobinopathy community, there has never been a more important time to help shape what comes next for patients.
We are looking for a passionate and experienced Associate Director of Patient Advocacy to partner with the haemoglobinopathies community and lead our global patient advocacy work — ensuring that the voices of those living with conditions like SCD and thalassemia sit at the very heart of Novo Nordisk’s access strategy and external engagement.
If you have a passion for improving the lives of people living with sickle cell disease and thalassemia, we would love to hear from you.
Apply now and be part of the story we are writing together with the haemoglobinopathy community.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?